



CERTIFICATE OF INSURANCE

Insured: All subsidiaries and affiliated engaged in clinical trials in the name of the named insured including the CRO's (Contract Research Organisations) and investigators.

This is to certify that policies of insurance listed below have been issued to the insured named above and are in force at this time. Regardless of any requirement, contractual agreement or other documentation for which this certificate is being requested or may pertain, the insurance coverage afforded by the captioned policy will be limited to and still subject to its original terms, conditions and exclusions. This certificate is issued as a matter of information only and confers no rights upon the certificate holder. It does not amend, extend or alter the coverage afforded by the policy listed below:-

Policy No:	P1025200001/9999/106914		
Certificate No:	P1025200001/9999/106914 - D702NC00001	Date:	23-07-2026
In Type of Insurance:	Clinical Trials Liability Insurance		
Name of the Insurer:	MAGMA GENERAL INSURANCE LTD		
Name of the Insured:	ASTRAZENECA PHARMA INDIA LIMITED		
Address of the Insured:	Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560045		
Additional Insured:			
Period of Insurance	From: 1st March 2026 To 28th February 2027		
Country of Performance:	Clinical Trials in India		
Limits of Liability:	Annual aggregate Limit: INR 82,987,552 per Occurrence and INR 165,975,104 per Aggregate		
	Limit per Protocol: INR 82,987,552 per Occurrence and INR 165,975,104 per Aggregate		
	Limit per tested Person: INR 8,298,755 per Occurrence		
Study No./Protocol No.:	D702NC00001		
Phase:	III		
Study Title:	Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)		
Sponsor of the Study:	AstraZeneca AB		
Local Contact:	ASTRAZENECA PHARMA INDIA LIMITED		
Planned Study Start (FPFV)	01-03-2026		
Planned Study End (LPLV)	31-08-2027		
No..of Subjects/Patients:	55		
Jurisdiction	India		
Deductible	NIL		
Investigator Details	1. Dr. Kaushal Kalra, VMMC and Safdarjung Hospital, Ansari Nagar East, near to AIIMS Metro Station, New Delhi, Delhi 110029 2. Dr. Vikas Ostwal, TMH, Dr. E Borges Road, Parel, Mumbai - 400 012 India 3. Dr. Chethan R, All India Institute of Medical Sciences, Sri Aurobindo Marg, Ansari Nagar, Ansari Nagar East, New Delhi, Delhi 110029 4. Dr. Aman Sondoule, HCG Manavata Cancer Center, Manavata Health Campus-Mumbai Naka, Nashik, Maharashtra, 422002 5. Dr. Praveen Adusumilli, Kolhapur Cancer Centre Private limited, R. S. No. 238, opp. Mayur Petrol Pump, Gokul Shirgaon, Maharashtra 416004 6. Dr. Naga Avinash Bonda. AIG Hospitals (A unit of Asian Institute of Gastroenterology) Survey No. 136, Plot No. 2/3/4/5, Mindspace Road, Gachibowli Hyderabad – 500 032, Telangana, India 7. Dr. Nihanthy D S, Saroj Gupta Cancer Centre & Research Institute, Mahatma Gandhi Road, Thakurpukur, Kolkata-700063, West Bengal, India 8. Dr. Ankit Patel, Unique Hospital Multispeciality and Research Institute, Nr. Kiran Motors, Opp Unique B.R.T.S Junction, Civil Hospital Char Rasta, Sosyo Circle Lane, Off Ring Road, Surat - 395017, Gujarat, India 9. Dr. Prashant Pandey, Tata Medical Centre, 14 MAR(E-W), Newtown, Rajarhat, Kolkata-700160, India		
Special Remarks if any	This certificate, issued, describes insurance cover in force on the day of issuance. The coverage provided is subject to all terms, conditions and exclusions afforded by the Insurance policy. In case of cancellation or other arrangements which alters the scope and/or validity of cover after date stated above, Magma General Insurance Ltd. will not bear any responsibility towards policyholder and/or third party other than agreed to in the original policy documents. This insurance is an integrated part of the Master policy for ASTRAZENECA PHARMA INDIA LIMITED It is hereby confirmed that the coverage provided by this policy covers the trial for its entire duration post the retroactive date and within the policy territory arising out of the Business of the Insured as stated in the Schedule. The coverage is therefore given for the entire life of the trial as per policy terms and conditions subject to the continuous renewal of policy with Magma.		

for **MAGMA GENERAL INSURANCE LTD**



Authorised Signatory

PLACE : **Mumbai**

23-07-2026

Magma General Insurance Limited (erstwhile Magma HDI General Insurance Company Limited) | www.magmainurance.com | E-mail: customercare@magmainurance.com | Toll Free: 1800 266 3202 | Registered Office: Development House, 24 Park Street, Kolkata – 700016, West Bengal. | CIN: U66000MH2009PLC4606933 | IRDAI Reg. No. 149 | CLINICAL TRIALS LIABILITY POLICY (COMMERCIAL) | Product UIN: IRDAN149CP0012V01201213| For complete list of details on exclusions, risk factors, terms & conditions, please read the policy documents carefully before concluding a sale. | Trade Logo displayed above belongs to Magma Ventures Private Limited and is used by Magma General Insurance Limited under license. | Chat with MIRA on our website or say "Hi" on WhatsApp No. 7208976789 (PW.CT.ver10.12.24)